Arena Stock Hits New 52-Week Low (ARNA)

NEW YORK ( TheStreet) -- Arena Pharmaceuticals (Nasdaq: ARNA) hit a new 52-week low Friday as it is currently trading at $6.91, below its previous 52-week low of $6.95 with 2.1 million shares traded as of 9:56 a.m. ET. Average volume has been 5.7 million shares over the past 30 days.

Arena has a market cap of $1.61 billion and is part of the health care sector and drugs industry. Shares are down 17.8% year to date as of the close of trading on Wednesday.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Arena as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. You can view the full Arena Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..

null

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets